Hepatitis Therapeutics Global Market Report 2025

Description

Hepatitis denotes inflammation of the liver caused by various viruses and non-viral factors. Hepatitis therapeutics encompasses medications designed to treat all forms of hepatitis, with immune modulators and oral antivirals being the primary drugs employed.

The principal disease types addressed through hepatitis therapeutics include hepatitis A, hepatitis B, hepatitis C, and other related conditions. Hepatitis A involves liver inflammation that can manifest as mild to severe illness. These therapeutics are categorized based on drug class into oral antivirals and immune modulators, with distribution channels extending to hospital pharmacies, drug stores, retail pharmacies, and online providers.

The hepatitis therapeutics market research report is one of a series of new reports from The Business Research Company that provides hepatitis therapeutics optical components market statistics, including hepatitis therapeutics optical components industry global market size, regional shares, competitors with a hepatitis therapeutics optical components market share, detailed hepatitis therapeutics optical components market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis therapeutics optical components industry. This hepatitis therapeutics optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatitis therapeutics market size has grown steadily in recent years. It will grow from $18.66 billion in 2024 to $19.27 billion in 2025 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to vaccine development, antiviral medications, public health initiatives, research funding, emerging therapies.

The hepatitis therapeutics market size is expected to see steady growth in the next few years. It will grow to $22.75 billion in 2029 at a compound annual growth rate (CAGR) of 4.2%. The growth in the forecast period can be attributed to continued research and development, global health efforts, shift in patient care, government initiatives, rising disease awareness. Major trends in the forecast period include patient advocacy and support, continuous monitoring and follow-up, healthcare equity, telemedicine and remote care, focus on hepatitis c elimination.

The hepatitis therapeutic market is anticipated to experience growth due to the global rise in hepatitis infections. The surge in hepatitis cases can be attributed to factors such as inadequate access to healthcare and vaccinations, increased intravenous drug use, unsafe blood transfusion practices, and suboptimal sanitation and hygiene conditions in certain regions. As of April 2022, the World Health Organization (WHO) reported at least 169 cases of acute hepatitis of unknown origin in 11 nations, with an estimated 350 million individuals worldwide affected by viral hepatitis B or C. However, for the majority of affected individuals, testing and treatment remain inaccessible. Consequently, the hepatitis therapeutics market is expanding in response to the escalating prevalence of hepatitis infections.

The increasing number of clinical trials is expected to drive the growth of the hepatitis therapeutic market in the future. Clinical trials are research studies that assess new treatments, medications, or interventions in human participants. They are essential for developing new hepatitis therapeutics, providing a rigorous and ethical framework for evaluating the safety and efficacy of potential treatments, and ensuring that patients have access to the most effective therapies available. For instance, in November 2023, the Association of the British Pharmaceutical Industry, a UK-based non-profit organization, reported a slight increase of 4.3% in the total number of industry-initiated clinical trials in the UK, rising from 394 trials in 2021 to 411 in 2022. Therefore, the rising number of clinical trials is contributing to the growth of the hepatitis therapeutics market.

A key trend in the hepatitis therapeutics market is the emergence of product innovations. Major companies in the market are actively involved in developing new products to maintain their market position. In November 2022, Gilead Sciences, Inc., a US-based biopharmaceutical company, obtained FDA approval for Vemlidy (tenofovir alafenamide) to treat pediatric patients with chronic hepatitis B virus infection. Vemlidy, a targeted prodrug of tenofovir, was initially approved in 2016 as a once-daily treatment for chronic hepatitis B virus infection and compensated liver disease in adults. It is recognized as a preferred or first-line treatment according to recommendations from the American Liver Foundation.

Strategic agreements have become a focal point for major companies operating in the hepatitis therapeutics market, aimed at gaining a competitive edge. In October 2023, GlaxoSmithKline plc, a UK-based pharmaceutical and biotechnology company, announced an exclusive licensing agreement for JNJ-3989, an investigational subcutaneous RNA interference therapeutic designed for treating chronic hepatitis B (CHB). JNJ-3989 is an innovative RNA interference therapeutic targeting the hepatitis B virus (HBV) X protein, which is crucial for HBV replication and persistence.

In February 2024, Gilead Sciences Inc., a pharmaceutical company based in the United States, acquired Cymabay Therapeutics, Inc., for an undisclosed sum. This acquisition is intended to strengthen Gilead's liver disease portfolio by incorporating seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to meet unmet medical needs and enhance treatment options for patients with chronic liver conditions. Cymabay Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the US that specializes in developing innovative therapies for chronic diseases, particularly those affecting the liver and diabetes.

Major companies operating in the hepatitis therapeutics market include Gilead Sciences Inc., Bristol-Myers Squibb Co., AbbVie Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Cipla Inc., F Hoffmann-La Roche Ltd., Biocon Limited, LAURUS Labs Ltd., Zydus Lifesciences Limited, Hetero Healthcare Limited, Novartis AG, Sanofi SA, GlaxoSmithKline plc, Lupin Ltd., Teva Pharmaceutical Industries Ltd., NATCO Pharma Limited, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Biocon Biopharmaceuticals Pvt. Ltd.

North America was the largest region in the hepatitis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the hepatitis therapeutics market report during the forecast period. The regions covered in the hepatitis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hepatitis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatitis therapeutics market consists of revenues earned by entities by providing services such as lifestyle modifications, nutritional support, and liver transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis therapeutics market also includes sales of corticosteroids, immune globulins, and Immune globulins which are used in providing hepatitis therapeutics services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatitis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hepatitis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatitis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepatitis therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Disease Type: Hepatitis A; Hepatitis B; Hepatitis C; Other Disease Types
2) By Drug Class: Oral Antivirals; Immune Modulators
3) By Distribution Channel: Hospital Pharmacies; Drug Stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Hepatitis A: Vaccines; Post-Exposure Prophylaxis (PEP)
2) By Hepatitis B: Antiviral Medications; Immune Modulators; Vaccines
3) By Hepatitis C: Direct-Acting Antivirals (DAAs); Ribavirin; Interferon-Based Therapies
4) By Other Disease Types: Hepatitis D; Hepatitis E; Other Viral Hepatitis Infections
Companies Mentioned: Gilead Sciences Inc.; Bristol-Myers Squibb Co.; AbbVie Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r23431

1. Executive Summary

2. Hepatitis Therapeutics Market Characteristics

3. Hepatitis Therapeutics Market Trends And Strategies

4. Hepatitis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hepatitis Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Hepatitis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hepatitis Therapeutics Market Growth Rate Analysis
5.4. Global Hepatitis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hepatitis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hepatitis Therapeutics Total Addressable Market (TAM)

6. Hepatitis Therapeutics Market Segmentation

6.1. Global Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis A
Hepatitis B
Hepatitis C
Other Disease Types
6.2. Global Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral Antivirals
Immune Modulators
6.3. Global Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Drug Stores And Retail Pharmacies
Online Providers
6.4. Global Hepatitis Therapeutics Market, Sub-Segmentation Of Hepatitis A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Post-Exposure Prophylaxis (PEP)
6.5. Global Hepatitis Therapeutics Market, Sub-Segmentation Of Hepatitis B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiviral Medications
Immune Modulators
Vaccines
6.6. Global Hepatitis Therapeutics Market, Sub-Segmentation Of Hepatitis C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Direct-Acting Antivirals (DAAs)
Ribavirin
Interferon-Based Therapies
6.7. Global Hepatitis Therapeutics Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis D
Hepatitis E
Other Viral Hepatitis Infections

7. Hepatitis Therapeutics Market Regional And Country Analysis

7.1. Global Hepatitis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hepatitis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hepatitis Therapeutics Market

8.1. Asia-Pacific Hepatitis Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hepatitis Therapeutics Market

9.1. China Hepatitis Therapeutics Market Overview
9.2. China Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hepatitis Therapeutics Market

10.1. India Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hepatitis Therapeutics Market

11.1. Japan Hepatitis Therapeutics Market Overview
11.2. Japan Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hepatitis Therapeutics Market

12.1. Australia Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hepatitis Therapeutics Market

13.1. Indonesia Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hepatitis Therapeutics Market

14.1. South Korea Hepatitis Therapeutics Market Overview
14.2. South Korea Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hepatitis Therapeutics Market

15.1. Western Europe Hepatitis Therapeutics Market Overview
15.2. Western Europe Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hepatitis Therapeutics Market

16.1. UK Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hepatitis Therapeutics Market

17.1. Germany Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hepatitis Therapeutics Market

18.1. France Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hepatitis Therapeutics Market

19.1. Italy Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hepatitis Therapeutics Market

20.1. Spain Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hepatitis Therapeutics Market

21.1. Eastern Europe Hepatitis Therapeutics Market Overview
21.2. Eastern Europe Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hepatitis Therapeutics Market

22.1. Russia Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hepatitis Therapeutics Market

23.1. North America Hepatitis Therapeutics Market Overview
23.2. North America Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hepatitis Therapeutics Market

24.1. USA Hepatitis Therapeutics Market Overview
24.2. USA Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hepatitis Therapeutics Market

25.1. Canada Hepatitis Therapeutics Market Overview
25.2. Canada Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hepatitis Therapeutics Market

26.1. South America Hepatitis Therapeutics Market Overview
26.2. South America Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hepatitis Therapeutics Market

27.1. Brazil Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hepatitis Therapeutics Market

28.1. Middle East Hepatitis Therapeutics Market Overview
28.2. Middle East Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hepatitis Therapeutics Market

29.1. Africa Hepatitis Therapeutics Market Overview
29.2. Africa Hepatitis Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hepatitis Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hepatitis Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hepatitis Therapeutics Market Competitive Landscape And Company Profiles

30.1. Hepatitis Therapeutics Market Competitive Landscape
30.2. Hepatitis Therapeutics Market Company Profiles
- 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Bristol-Myers Squibb Co. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hepatitis Therapeutics Market Other Major And Innovative Companies

31.1. Cipla Inc.
31.2. F Hoffmann-La Roche Ltd.
31.3. Biocon Limited
31.4. LAURUS Labs Ltd.
31.5. Zydus Lifesciences Limited
31.6. Hetero Healthcare Limited
31.7. Novartis AG
31.8. Sanofi SA
31.9. GlaxoSmithKline plc
31.10. Lupin Ltd.
31.11. Teva Pharmaceutical Industries Ltd.
31.12. NATCO Pharma Limited
31.13. Pfizer Inc.
31.14. AstraZeneca plc
31.15. Boehringer Ingelheim International GmbH

32. Global Hepatitis Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hepatitis Therapeutics Market

34. Recent Developments In The Hepatitis Therapeutics Market

35. Hepatitis Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Hepatitis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Hepatitis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Hepatitis Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer